Maxi Investments CY Ltd Buys 32,500 Shares of Tempus AI, Inc. $TEM

Maxi Investments CY Ltd bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 32,500 shares of the company’s stock, valued at approximately $2,662,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Apollon Wealth Management LLC raised its holdings in shares of Tempus AI by 26.8% during the 3rd quarter. Apollon Wealth Management LLC now owns 6,872 shares of the company’s stock worth $563,000 after acquiring an additional 1,451 shares in the last quarter. Capelight Capital Asset Management LP purchased a new position in shares of Tempus AI in the third quarter valued at $4,095,000. Signaturefd LLC grew its holdings in shares of Tempus AI by 102.7% in the third quarter. Signaturefd LLC now owns 1,865 shares of the company’s stock valued at $153,000 after purchasing an additional 945 shares in the last quarter. Citizens Financial Group Inc. RI bought a new stake in Tempus AI in the third quarter worth $324,000. Finally, Ascent Wealth Partners LLC bought a new stake in Tempus AI in the third quarter worth $288,000. Institutional investors own 24.22% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Ryan M. Bartolucci sold 7,062 shares of the stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $75.00, for a total value of $529,650.00. Following the sale, the chief accounting officer directly owned 60,804 shares in the company, valued at approximately $4,560,300. This represents a 10.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nadja West sold 3,000 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $69.00, for a total value of $207,000.00. Following the completion of the sale, the director owned 31,981 shares in the company, valued at approximately $2,206,689. The trade was a 8.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,030,965 shares of company stock valued at $69,882,564 over the last quarter. Corporate insiders own 24.26% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on TEM. Weiss Ratings raised shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Raymond James Financial set a $80.00 price objective on shares of Tempus AI in a research note on Wednesday, September 2nd. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a report on Tuesday, June 30th. HC Wainwright upped their target price on shares of Tempus AI from $66.00 to $68.00 and gave the company a “buy” rating in a research report on Monday. Finally, UBS Group started coverage on shares of Tempus AI in a report on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price target for the company. Eleven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $72.47.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: EU regulatory certification: Tempus announced that its xR RNA sequencing assay received Class C certification under the European Union’s In Vitro Diagnostic Regulation. The certification covers solid-tumor profiling and supports the company’s ability to market the test for clinical management in Europe, potentially expanding adoption and revenue opportunities. Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling
• Positive Sentiment: AI drug-development collaboration: Tempus is participating in a strategic collaboration with Pathos AI and Bristol Myers Squibb focused initially on Alzheimer’s disease and other neurological conditions. The agreement reinforces Tempus’ role in AI-enabled drug development and could create longer-term data and collaboration opportunities, although financial terms were not provided. Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst support: BTIG reaffirmed its “buy” rating and maintained an $80 price target, implying meaningful upside from the stock’s recent level. BTIG Research stock recommendations
• Neutral Sentiment: Earnings setup: Zacks expects Tempus to have favorable conditions for beating estimates in its upcoming report. A beat could support the shares, but the article reflects expectations rather than reported results. Tempus AI expected earnings estimates
• Negative Sentiment: Cash-burn concerns: Continued cash consumption could pressure Tempus’ valuation and increase the need for financing, particularly because the company remains unprofitable and has a high debt-to-equity ratio. What Happens To Tempus AI Stock If Its Cash Burn Continues?
• Neutral Sentiment: Short-interest data: The latest report lists no measurable short interest and a zero-day short-interest ratio, suggesting little evidence of short-covering activity as a current catalyst.

Tempus AI Trading Down 0.7%

TEM stock opened at $67.16 on Tuesday. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $93.38. The stock has a market capitalization of $12.12 billion, a price-to-earnings ratio of -46.64 and a beta of 3.54. The firm’s fifty day simple moving average is $69.29 and its two-hundred day simple moving average is $56.94.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The business had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same quarter in the prior year, the firm posted ($0.22) earnings per share. The business’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, analysts anticipate that Tempus AI, Inc. will post -1.43 earnings per share for the current year.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.